Since miHag specific alloresponses after donor lymphocyte infusions are of substantial clinical relevance in graft-versus-leukemia effects,23 we conclude that EBAG9 defines a crucial checkpoint for the cytolytic capacity of CD8+ T cells and may hence be suitable for therapeutic exploitation. Here, EBAG9 is linked to leukemia.